# Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer

> **NCT00084396** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 115 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** letrozole
- **PROCEDURE:** conventional surgery

## Key facts

- **NCT ID:** NCT00084396
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2007-03
- **Final completion:** 2016-09
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2016-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084396, "Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00084396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*